MARK2 and cancer: The remaining 18 targets (3 Tyrosine Kinases-Like, TKLs; 15 Serine-Threonine Kinases, STKs) were selected among the remaining kinases in the ScanEDGE subset on the basis of their well established role in cancer (see Fig. S2 for a graphical representation of the selected kinases with reference to the kinome tree.